


AZ7976

Cat. No.:	HY-162401
CAS No.:	2813866-27-0
Molecular Formula:	C ₃₀ H ₃₃ F ₇ N ₂ O ₆ S
Molecular Weight:	682.65
Target:	RXFP Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description AZ7976 (Compound 42) is a highly selective agonist for the Relaxin Family Peptide Receptor 1 (RXFP1) (pEC₅₀ > 10.5). AZ7976 enhances RXFP1's cAMP signaling through an allosteric mechanism, thereby physiologically increasing heart rate. AZ7976 can be used in the field of cardiovascular disease [1].

In Vitro AZ7976 (90 min; concentration responses) does not compete with relaxin H2 for binding to RXFP1 in CHO-hRXFP1 cells, but enhances 125I-relaxin H2 binding [1]. AZ7976 inhibits ion channels and bile salt efflux transporter (BSEP) and is cytotoxic to THP1 [1].

In Vitro Safety [1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC ₅₀ THP1	IC ₅₀ HepG2 Glu/Gal	IC ₅₀ HepG2 C3a spheroids	IC ₅₀ BSEP	IC ₅₀ hERG	IC ₅₀ Nav1.5	IC ₅₀ Kv4.3 (Ito)	IC ₅₀ IKs	mic
42 μM	15 μM	68/37 μM	17 μM	23 μM	>39 μM	21 μM	>33 μM	>33 μM

In Vivo

AZ7976 (i.v.; initial 1.5 mg/kg; i.v.drip; continuous 9.0 mg/kg) causes a significant increase in heart rate and a rise in mean arterial blood pressure in the rats. [1].

Pharmacokinetic Analysis in AZ7976 [1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Route	Dose (μg)	Vdss	Cl	t _{1/2}	oral	F
-------	-----------	------	----	------------------	------	---

mol/kg)(L/kg)(mL/min/kg)_{1/2} dose (μ (%)(h) mol/kg)

i.v. 0.73 2.3 38 2.9 1.46 11

Animal Model: Sprague-Dawley rats^[1]

Dosage: initial 1.5 mg/kg,
continuous 9.0 mg/kg

Administration: i.v.; i.v.drip

Result: Caused a significant increase in heart rate and a rise in mean arterial blood pressure in the rats, the same response in Sprague-Dawley rats as after RXFP1 receptor activation

REFERENCES

[1]. Granberg KL, et al. Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists. J Med Chem. 2024 Mar 28;67(6):44

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA